Alnylam Pharmaceuticals, Inc.

Good day, and thank you for standing by. Welcome to the Alnalyme Pharmaceuticals Q4 2023 Earnings Conference Call. At this time, participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. Please be advised that today's conference is being recorded. I would now like to hand the conference call over to the company.

Good morning. I'm Christine Lindeboom, Senior Vice President of Investor Relations and Corporate Communications at Alnylam. With me today are Yvonne Greenstreet, Chief Executive Officer, Tolga Tangular, Chief Commercial Officer, Pushkal Garg, Chief Medical Officer, and Jeff Holton, Chief Financial Officer. Also on the line and available for Q&A is Akshay Vishnow, Chief Innovation Officer. For those of you participating via conference call, the accompanying slides can be accessed by going to the events section of the investors page of our website, investors.alnylam.com slash events. During today's call, as outlined in slide two, Yvonne will offer some introductory remarks and provide general context. Tova will provide an update on our global commercial progress. Pushka will review pipeline updates and clinical progress. And Jeff will review our financials and guidance, followed by a summary of upcoming milestones before we open the call for your questions. I would like to remind you that this call will contain remarks concerning L&ILAM's future expectations, plans, and prospects, which constitute forward-looking statements for the purposes of the safe harbor provision of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in our most recent periodic report on file with the SEC. In addition, any forward-looking statements represent our views only of the date of this recording and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update such statements. With that, I'll turn it over to Yvonne.

Yvonne? Thanks, Christine, and thank you, everyone, for joining the call today. Alnyla made great strides in 2023, delivering strong progress across all areas of our business. This includes the robust product growth for our four wholly-owned commercial medicines, delivering $1.24 billion in global net product revenues, and hitting the remarkable milestone of over 5,000 patients now on an alnylam commercial RNAi therapeutic. We also extended our leadership on RNAi, including the first-ever demonstration of RNAi-mediated target gene silencing of the human brain and preclinical data showing, for the first time, delivery of RNAi therapeutics for adipose and muscle tissues. Zalbitran also made exciting progress for hypertension, with encouraging results in the CARDIA-1 Phase 2 study. Further, with Zalbiceran, we strengthened our business for the future through business development with a landmark collaboration with Bosch. Looking forward, we're excited to continue this progress in 2024, delivering continued commercial execution, notable clinical trial readouts, and advancing programs across all stages of development. As you're aware, a key clinical milestone anticipated this year is the readout from our HEDIS-B Phase III study of butreceram in patients with ATTR amyloidosis with cardiomyopathy. As we indicated in our press release this morning, we're announcing a few updates to the analysis plan that we believe will enhance the study, enable the best demonstration of butreceram's impact across the entirety of the patient population, and support a strong and competitive label. Pushkar will walk through these updates in detail later in the call. We believe all of this puts us on track with our Arnylam piece of fifth by 25 goals, making Arnylam a top-tier biotech, developing and commercializing transformative medicines for patients around the world with rare and prevalent diseases, driven by a high-yielding pipeline of first and or best-in-class product candidates from our organic product engine, all while delivering exceptional financial results. With that, let me now turn the call over to Tolga for a review of our commercial performance. Tolga?